Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market
EyeBio Raises $65m In Series A
Executive Summary
Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.
You may also be interested in...
Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?
There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.
Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.